Revenue Recognized from Contract Liability
Vertex Pharmaceuticals Revenue Recognized from Contract Liability remained flat by 0.0% to $51.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 21.4%, from $42.58M to $51.70M. Over 2 years (FY 2023 to FY 2025), Revenue Recognized from Contract Liability shows an upward trend with a 13.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher values indicate successful delivery of services or products for which cash was previously received.
Detailed definition
Revenue recognized during the current period that was previously recorded as a contract liability (deferred revenue) at...
Peer comparison
Commonly disclosed in revenue recognition notes for companies with subscription or long-term contract models.
tmusz_contract_liability_revenue_recognizedHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $159.60M | $170.30M | $206.80M |
| YoY Change | — | +6.7% | +21.4% |
Revenue Recognized from Contract Liability at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's revenue recognized from contract liability?
- Vertex Pharmaceuticals (VRTX) reported revenue recognized from contract liability of $51.70M in Q4 2025.
- How has Vertex Pharmaceuticals's revenue recognized from contract liability changed year-over-year?
- Vertex Pharmaceuticals's revenue recognized from contract liability increased by 21.4% year-over-year, from $42.58M to $51.70M.
- What is the long-term trend for Vertex Pharmaceuticals's revenue recognized from contract liability?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's revenue recognized from contract liability has grown at a 13.8% compound annual growth rate (CAGR), from $159.60M to $206.80M.
- What does revenue recognized from contract liability mean?
- Revenue recognized this period that was previously collected as deferred revenue.